Ottawa, CANADA (August 2, 2022) – Cannabis Orchards Inc., a biotechnology company focusing on the research, development and commercialization of minor cannabinoids and innovative industrial hemp varieties, announced it has signed an exclusive distribution agreement with Trilogene Seeds, an American cannabis and hemp genetics platform company based in Longmont, Colorado, that prioritizes the breeding and growing of unique feminized hemp varieties including extraction grade, tri-crop and smokable varieties, with an overarching goal of stabilizing their genetics and making their catalogue of varieties available internationally.

Cannabis Orchards Inc. will exclusively distribute feminized hemp seed from select Trilogene varieties and genetics, which align with the collective goal of making available hemp varieties rich in CBD and minor cannabinoids, upon approval by Health Canada. These varieties include: 

• Vendetta
  • Near 1:1 ratio of CBD:CBDV
• Red Robin:
  • 36:1 CBD:THC
  • Plants are uniquely red in colour with high terpene content
• Auto Glu
  • High-CBD auto-flower variety
• Super Woman
  • 34:1 CBD:THC with up to 18% CBD in flower
  • Balanced hybrid which thrives in multiple climates
• Ultra Pink
  • 36:1 CBD:THC, with yields of up to 4 pounds per plant
  • Purple bud structure with loads of resin

Statement from Cannabis Orchards Inc. CEO, Dr. Jamie Ghossein

“The partnership agreement with Trilogene will enable us to offer many innovative industrial hemp varieties to Canadian growers, which will help our industry catch up to the next generation of hemp genetics offered in the USA. This includes high performing CBD varieties and auto flower genetics. 

More importantly, this will enable us to scale the production of CBDV.  We can now offer this minor cannabinoid to Cannabis companies, researchers and consumers alike. We have still a lot to learn about CBDV, but based on our review of the basic science literature, our team is thrilled with the exciting therapeutic potential of this minor cannabinoid.”

About Cannabis Orchards

Cannabis Orchards Inc. is an inventive, research-driven, and proudly Canadian company focused on furthering the development and commercialization of novel cannabinoids and therapeutics. The company is highly research-motivated and leads research into the development of new hemp varieties, and their applications in clinic. In clinic, the company has an involved focus on producing the highest quality hemp flowers for their medicinal contents. Cannabis Orchards products are highly sought after by Licensed Processors, research institutes and pharmaceutical companies. For more information on Cannabis Orchards Inc., visit https://www.cannabisorchards.ca

About Trilogene Seeds

Trilogene Seeds is composed of an extremely qualified team of breeders, cultivators and cannabis industry professionals. The company’s goal is the creation, and stabilization of varieties of Elite Hemp Genetics for the U.S. and international hemp cannabinoid market. Trilogene Seeds offers feminized hemp seeds for multiple industries with tri-crop, smokable and extraction grade hemp varieties. For more information about Trilogene Seeds visit: https://trilogeneseeds.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Company Reports Its Q1 2022 Results and Provides Comments on Operations

VANCOUVER, British Columbia, July 19, 2022 (GLOBE NEWSWIRE) — Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva,” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, today highlights its financial and operating results for Q1 of 2022.

$1.16 million of revenue was generated in Q1 2022, almost double the $.58 million of revenue in the same period for the prior year. This growth was driven by increased sales in both its retail business operations as well as sales of wholesale bulk cannabis flower. Net loss for the quarter decreased from $5.5 million in Q1 2021 to $3 million in Q1 2022.

In the first quarter of 2022, Juva advanced JUVA-019, a proprietary novel compound that has previously demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation, from discovery into preclinical development. It also advanced JUVA-041, a second proprietary novel compound into preclinical development, further substantiating the Company’s discovery strategy and technology platform. Juva Life has filed patents on both compounds and plans to advance them through the standardized clinical stage gate in the coming months. Also on the clinical side of the Company, Juva launched the Journal App that offers cannabis users a daily tracking solution to monitor how their cannabis consumption affects their personal health and wellness, furthering Juva’s mission of proving the therapeutic value of cannabis.

Additionally, the Company completed the final phase of construction of its 30,000-square-foot Stockton cultivation facility, which more than doubled the growing capacity of the facility without adding additional costs, and maximizing the facility’s cultivation systems.

“As we move to the second half of the year, we are feeling extremely confident about our progress in both our life sciences research and cannabis operations,” said Doug Chloupek, CEO and Founder of Juva. “Our research team is moving at an unparalleled pace in proving the potential therapeutic value of both of our lead candidates, JUVA-019 and JUVA-041. We have already seen extremely promising preclinical results in their ability to inhibit inflammation, and we are moving them forward in their clinical pipeline as quickly as possible. On the cannabis operations side, our cultivation facility in Stockton is fully complete and firing on every cylinder. The delivery business is continuing to grow, and we are so excited to have received one of the first and only retail licenses in Redwood City. All in all, Q1 was a great first quarter for Juva, and we are looking forward to sharing our Q2 results in short order.”

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

[email protected]

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: [email protected]

Investor Relations:
Kyle Porter
858.221.8001
[email protected]

Corporate Contact:
1.833.333.JUVA (5882)

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Vancouver, British Columbia – December 30, 2021 – Lotus Ventures Inc. (CSE: J) (OTC: LTTSF) (“Lotus” or the “Company”), a trusted cannabis producer in Canada is pleased to report its Fiscal 2021 full year results and a second consecutive year reporting a profit for the year ended August 31, 2021.

• Full year revenue increased to $5.4 million up 18 percent compared to the prior year.

• Fourth quarter revenue of $1.2 million, a decrease compared to the prior year due to the Company realizing a more consistent Fair Value on Biological Asset accounting process.

• Lotus achieved positive EBITDA and positive net income in each of the first two years of production. One of the unique publicly traded licensed producers to accomplish this in the first three years of Canadian adult-use legalization.

• Gross margin before fair value adjustments for the full year ended was 45 percent.

• The Company is in the final stages of securing non-dilutive financing with an institutional lender for Phase 2 of the Controlled Environment Agriculture facility located near Armstrong, B.C.

“Lotus’ continued growth this year demonstrates our operating strength and resilience, and it couldn’t be done without the commitment from our whole team,” said Dale McClanaghan, President & CEO, Lotus. “Our Fiscal 2021 was a year of modest growth, as we sold over 2 million grams of cannabis and reached the milestone of $10 million in sales since we first started two years ago. Fueled by our expansion growth in the North Okanagan, we are excited to invest in additional growing capacity to expand our premium cannabis portfolio and supply more unique and premium strains like our Kalifornia in the new year.”

The following selected financial information is derived from the Company’s audited financial statements for the years ended August 31, 2021, 2020 and 2019.

During the year ended August 31, 2021, the Company had net income of $241,097 (2020 – $1,494,002). The financial results of the Company for the eight most recent quarters are summarized below:

The Annual Financial Statements and Management Discussion and Analysis for the year ended August 31, 2021, is available on sedar.com

ON BEHALF OF THE BOARD:
Lotus Ventures Inc.
“Dale McClanaghan”
Dale McClanaghan, President and CEO

About Lotus Ventures Inc. (CSE: J)
Lotus Ventures Inc. is a licensed cannabis producer and the owner of Lotus Cannabis Co., a premium consumer brand in Canada. The Lotus team specializes in commercial cannabis production using a Controlled Environment Agriculture facility built in the North Okanagan of British Columbia.

Lotus has reached consumers in nine provinces to date through wholesale relationships across Canada and our flower has been sold in both the premium and ultra-premium segments of the market by wholesale partners. Lotus looks to launch its own product offerings in the recreational market over the next year and has several unique strains in development.

Lotus Ventures Inc. is listed on the Canadian Securities Exchange under the symbol J and on the OTC Markets under the symbol LTTSF.

For Further Information:

President & CEO
Dale McClanaghan
[email protected]
604-644-9844

Investor Relations
Daniel McRobert
[email protected]
604-842-4625

To learn more, visit our website at lotuscannabis.ca or follow our brand on social media.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• Revenue of US$9.2 million, +43% sequentially; Adjusted EBITDA¹ of US$3.1 million, +27% sequentially.
• Adjusted fully diluted EPS of US$0.01.
• Phoenix dispensaries operated by VEXT generated successive record months in March 2021 and April 2021, with the trend continuing into May 2021².
• The Company will hold a conference call and webcast to discuss its Q1 financial results at 8:00 a.m. ET.

VANCOUVER, May 26, 2021 /CNW/ – Vext Science, Inc. (“Vext” or the “Company”) (OTCQX: VEXTF) (CSE: VEXT) a cannabinoid brand leader based in Arizona, leveraging its core expertise in extraction, manufacturing, cultivation, and marketing to build a profitable multi-state footprint, today reported its financial results for the period ended March 31, 2021. All currency references used in this news release are in U.S. currency unless otherwise noted.

Summary Financial Results (unaudited)

Management Commentary

Eric Offenberger, CEO of VEXT commented, “Our team generated strong financial performance in Q1, fueled by a record month in March for our operated Phoenix dispensaries. Momentum in the Arizona market continues to build, and with recent announcements of fully funded expansions to effectively triple our cultivation footprint and a four-fold expansion to our manufacturing space, we are prepared for the upcoming growth. Vext continues to translate solid top-line performance into expanding Adjusted EBITDA and positive fully diluted earnings per share. The Company has been profitable since 2016⁴ and we are committed to delivering organic growth for shareholders, while judiciously building our footprint in Arizona, both on the retail side of the business and through wholesale channels led by the strength of the Vapen brand.”

Summary of Recent Operating Developments

• On May 11, 2021, Vext announced that it had received approval from the City of Eloy to build and operate a state-of-the-art medical cannabis cultivation facility. As announced on April 7, 2021, Vext entered into a purchase and sale agreement to acquire a vacant 72,000 square foot industrial facility (~34,000 square feet of future canopy) located in the City of Eloy.
• On May 20, 2021, the Company announced that it had received approval from the State of Arizona to begin operations in its recently expanded, dedicated extraction and manufacturing facility located at 4215 N. 40th Avenue, Phoenix. Previously, the Company had been conducting extraction and manufacturing operations in space co-located with one of its cultivation facilities. As part of the move to a dedicated footprint, Vext increased overall space by four times and built additional automation into its processes. The expansion included: additional extract and concentrates production space; a tripling of the Company’s kitchen capacity in order to meet growing demand for edibles as the Arizona adult-use market develops; a re-designed finished goods area to support increased efficiency and throughput; and a dedicated product development lab, which the Company will utilize to continue innovating the Vapen line of branded products.

Q1-2021 Financial Results Conference Call

Vext will host a conference call and webcast Wednesday May 26, 2021, at 8:00 a.m. ET to discuss its first quarter financial results. The call will be chaired by Eric Offenberger, CEO and Vahan Ajamian, CFO:

Date: May 26, 2021 | Time: 8:00 a.m. ET

Participant Dial-in: 416-764-8609 or 1-888-390-0605

Replay Dial-in: 416-764-8677 or 1-888-390-0541

Conference ID: 67631670

Playback #: 631670 (Expires June 9, 2021)

Listen to webcast: https://bit.ly/2RfEtrf

Non-IFRS Financial Measures

The Company has provided certain non-IFRS financial measures including “Gross margin”, “Adjusted EBITDA” and “Adjusted EBITDA margin”. These non-IFRS financial measures do not have a standardized definition under IFRS, nor are they calculated or presented in accordance with IFRS and may not be comparable to similar measures presented by other companies. The Company defines “Gross margin as Gross Profit divided by Revenue. The Company defines “Adjusted EBITDA as net income (loss) from operations, as reported, before interest and tax, adjusted to exclude extraordinary items, non-recurring items, other non-cash items, including stock-based compensation expense, depreciation and amortization, foreign exchange and acquisition related costs, if applicable. The Company defines “Adjusted EBITDA margin” as Adjusted EBITDA divided by Revenue.

The Company has provided these non-IFRS financial measures as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. The Company believes that these supplemental non-IFRS financial measures provide a valuable additional measure to use when analyzing the operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein. The following tables provide a reconciliation of each of the non-IFRS measures to its closest IFRS measure.

Adjusted EBITDA

The following information provides reconciliations of the supplemental non-IFRS financial measure presented herein to the most directly comparable financial measure calculated and presented in accordance with IFRS.

About VEXT Science, Inc.

Vext Science, Inc. is a US-based Cannabis THC and Hemp cannabinoid products company manufacturing THC cartridges, concentrates, edibles, and accessories under the Vapen Brand, and Hemp based products under the Pure Touch Botanicals brand as well as the Vapen CBD brand. Based in Arizona, Vext Science, Inc. has one of the leading THC concentrates, edibles, and distillate cartridge brands sold in most of the state’s 100+ dispensaries. Herbal Wellness Center is one of Arizona’s leading dispensary banners and we execute all aspects of the cultivation, extraction, edibles infusion and manufacturing processes which ensures a product of the highest quality and purity. Product quality and purity are core to our marketing strategy. Vext Science, Inc. is executing its business growth by leveraging experience and expertise in extractions, product manufacturing, and marketing to expand in the U.S. through revenue and profit-sharing joint venture partnerships. For more information visit our website at www.VextScience.com.

For more details on the Vapen brand:
Vapen website: VapenBrands.com 
Instagram: @vapen 
Facebook: @vapenclear

COVID-19 Risk Factor

Vext may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19. An outbreak of infectious disease, a pandemic, or a similar public health threat, such as the recent outbreak of COVID-19, or a fear of any of the foregoing, could adversely impact Vext by causing operating, manufacturing, supply chain, and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Vext may be affected if such a pandemic persists for an extended period of time, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which VEXT is subject. Although VEXT has been deemed essential and/or has been permitted to continue operating its facilities in the states in which it operates during the pendency of the COVID-19 pandemic, there is no assurance that the Company’s operations will continue to be deemed essential and/or will continue to be permitted to operate. Vext may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition, and the trading price of the Company’s Common Shares.

Forward Looking Statements

This news release contains “forward-looking statements”. Wherever possible, words such as “may”, “would”, “could”, “should”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation: the Company’s outlook for and expected operating margins, capital allocation and other financial results; statements relating to the business and future activities of, and developments related thereto, the Company after the date of this news release; statements relating to the business and future activities of, and developments related thereto, the Company after the date of this news release, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company’s business, operations and plans; expectations regarding cultivation and manufacturing capacity; expectations of market size and growth in the U.S. and the states in which the Company operates; expectations for other economic business or competitive factors related to the Company; the Company’ business outlook, those listed in the annual information form of the Company dated September 17, 2020, the short form prospectus and the other filings made by the Company with the Canadian securities’ regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

The Canadian Securities Exchange has not reviewed, approved, or disapproved the content of this news release.

Eric Offenberger
Chief Executive Officer
844-211-3725

SOURCE VEXT Science, Inc.

For further information: Jonathan Ross, VEXT Investor Relations, [email protected], 416-283-0178

Related Links

https://vextscience.com/Results Q1

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• Dedicated extraction and manufacturing space positions Vext to meet growth in volume at its operated dispensaries and increased sales of its wholly owned Vapen brand across the state.
• Four-fold increase in overall space includes additional extract and concentrates production space, a tripling of kitchen capacity, a re-designed finished goods area to support increased throughput and a dedicated product development lab.

VANCOUVER, BC, May 20, 2021 /CNW/ – Vext Science, Inc. (“Vext” or the “Company”) (CSE: VEXT; OTCQX: VEXTF) a cannabinoid brand leader based in Arizona, leveraging its core expertise in extraction, manufacturing, cultivation and marketing to build a profitable multi-state footprint, announced today that it has received approval from the State of Arizona to begin operations in its recently expanded, dedicated extraction and manufacturing facility located at 4215 N 40th Avenue, Phoenix (the “Facility”). To date, the Company has been conducting extraction and manufacturing operations in space co-located with one of its cultivation facilities. As part of the move to a dedicated footprint, Vext increased overall space by four times and built additional automation into its processes. The expansion includes: additional extract and concentrates production space; a tripling of the Company’s kitchen capacity in order to meet growing demand for edibles as the Arizona adult-use market develops; a re-designed finished goods area to support increased efficiency and throughput; and a dedicated product development lab, which the Company will utilize to continue innovating the Vapen line of branded products.

Eric Offenberger, CEO of Vext commented, “The further development of our manufacturing capabilities will enable us to meet growing demand for Vapen branded product both at our operated dispensaries, and in the wholesale channel in Arizona. The expanded facility gives our team the capacity necessary to immediately increase production of extracts and concentrates, while continuing to push product development and innovation in our wholly owned Vapen product line to meet the evolving tastes and preferences of consumers. We recently announced a large, fully funded expansion to our wholly owned cultivation footprint and by moving extraction and manufacturing operations into a dedicated facility, we create room for additional biomass production until our Eloy facility comes online in early 2022. With robust upstream and downstream capacity in place, Vext is on track to continue solidifying its position in the Arizona market while generating financial results for shareholders.”

For more details, visit VEXT’s investor website or contact the IR team at [email protected].

About VEXT Science, Inc.

Vext Science, Inc. is a US-based Cannabis THC and Hemp cannabinoid products company manufacturing THC cartridges, concentrates, edibles and accessories under the Vapen Brand, and Hemp based products under the Pure Touch Botanicals brand as well as the Vapen CBD brand. Based in Arizona, Vext Science, Inc. has one of the leading THC concentrates, edibles, and distillate cartridge brands sold in most of the state’s 100+ dispensaries. Herbal Wellness Center is one of Arizona’s leading dispensaries and we execute all aspects of the cultivation, extraction, edibles infusion and manufacturing processes which insures a product of the highest quality and purity. Product quality and purity are core to our marketing strategy. Vext Science, Inc. is executing its business growth by leveraging experience and expertise in extractions, product manufacturing, and marketing to expand in the U.S. through revenue and profit-sharing joint venture partnerships. For more information visit our website at www.VextScience.com.

For more details on the Vapen brand:
Vapen website: VapenBrands.com
Instagram: @vapen
Facebook: @vapenclear

COVID-19 Risk Factor

VEXT may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19. An outbreak of infectious disease, a pandemic, or a similar public health threat, such as the recent outbreak of COVID-19, or a fear of any of the foregoing, could adversely impact VEXT by causing operating, manufacturing, supply chain, and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how VEXT may be affected if such a pandemic persists for an extended period of time, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which VEXT is subject. Although VEXT has been deemed essential and/or has been permitted to continue operating its facilities in the states in which it operates during the pendency of the COVID-19 pandemic, there is no assurance that the Company’s operations will continue to be deemed essential and/or will continue to be permitted to operate. VEXT may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of the Company’s Common Shares.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in VEXT’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should, on track” and similar expressions, are forward- looking statements.

Forward-looking statements may include, without limitation, statements related COVID-19, to future developments and the business and operations of VEXT, the Company’s market position in the State of Arizona, and the Company’s financial results, , and of which are subject to the risk factors contained in Vext’s continuous disclosure filed on SEDAR.

Although VEXT has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward- looking statements in this news release are made as of the date of this release. VEXT disclaims any intention or obligation to update or revise such information, except as required by applicable law, and VEXT does not assume any liability for disclosure relating to any other company mentioned herein.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Eric Offenberger
Chief Executive Officer
844-211-3725

SOURCE VEXT Science, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Cultivation Progressing at Arkansas Cultivation Facility

VANCOUVER, BC, May 6, 2021 /CNW/ – Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) (the “Company” or “BaM”), a multi-state operator, is pleased to provide an update on construction in Ohio and cultivation operations in Arkansas.

BaM and NMG Ohio LLC have completed construction of the Ohio production facility and are in the final stages of obtaining local and state permits for operation. The production facility is located next to the Body and Mind dispensary west of Cleveland and anticipates producing a wide variety of Body and Mind branded offerings for the Ohio market.

“Our award-winning Body and Mind products have proven success in Nevada and California and we’re looking forward to expansion to the Ohio market”, stated Michael Mills, CEO of Body and Mind. “We continue to see strong growth in the Ohio market and applaud the recent announcement regarding measured expansion of dispensary licenses in the limited license state. Ohio has a population of roughly 11.5 Million (2019 US Census) and there are currently 52 dispensaries which have received a certificate of operation of 57 provisional dispensary licenses awarded. We intend to apply for new licenses as the process opens and continue to advance additional license applications across other jurisdictions.”

Cultivation operations are advancing in Arkansas with Comprehensive Care Group. The cultivation facility was built out in 2020 and the required cultivation equipment has recently been installed. Last month, after receiving approval to begin cultivation operations from the State, seeds were sprouted and plant growth is now underway. “We look forward to increasing the number of plants over time as the state rules allow, and to be able to provide our Body and Mind flower quality to the patients of Arkansas,” stated Trip Hoffman, COO of Body and Mind.

Arkansas is a limited license medical state with a population of over three million (2019 US Census). The State has currently approved 38 dispensaries with a total of 32 dispensaries currently open and six anticipated to open in 2021. In 2020, a ballot initiative was launched to qualify adult-use measures, however, the campaign fell short on signatures stemming from challenges around the COVID-19 pandemic.

The Company is pleased to announce that it will be presenting next week at the Canaccord Cannabis Virtual Conference on Tuesday, May 11, 2021.

About Body and Mind Inc.

BaM is an operations focused multi-state operator investing in high quality medical and recreational cannabis cultivation, production and retail. Our wholly owned Nevada subsidiary was awarded one of the first medical marijuana cultivation licenses and holds cultivation and production licenses. BaM products include dried flower, edibles, oils and extracts as well as GPEN Gio cartridges. BaM cannabis strains have won numerous awards including the 2019 Las Vegas Weekly Bud Bracket, Las Vegas Hempfest Cup 2016, High Times Top Ten, the NorCal Secret Cup and the Emerald Cup.

BaM continues to expand operations in Nevada, California, Arkansas and Ohio and is dedicated to increasing shareholder value by focusing time and resources on improving operational efficiencies, facility expansions, state licensing opportunities as well as mergers and acquisitions.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Safe Harbor Statement
Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others, the actual results of activities, variations in the underlying assumptions associated with the estimation of activities, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, accidents, labor disputes and other risks. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities.

SOURCE Body and Mind Inc.

For further information: Investor Relations: Jonathan Paterson, +1 203 862 0492, [email protected]; Eric Balshin, +1 647 499 3746, [email protected]; Company Contact: Michael Mills, CEO, Tel: 800-361-6312, [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.